| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
249,248 |
214,381 |
$2.55M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
248,960 |
214,402 |
$2.54M |
| 87506 |
|
18,583 |
18,428 |
$2.07M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
171,688 |
164,084 |
$1.78M |
| 82274 |
|
157,839 |
156,512 |
$1.62M |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
147,369 |
146,964 |
$1.56M |
| 86235 |
|
16,137 |
15,994 |
$1.49M |
| 88185 |
|
1,813 |
1,725 |
$1.16M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
148,792 |
147,085 |
$1.15M |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
43,391 |
42,686 |
$1.12M |
| 88341 |
|
6,077 |
5,953 |
$882K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
95,421 |
93,715 |
$792K |
| 86803 |
|
143,565 |
142,442 |
$759K |
| 82043 |
|
149,213 |
147,464 |
$758K |
| 87088 |
|
173,698 |
164,338 |
$751K |
| 86780 |
|
157,840 |
155,731 |
$693K |
| 88342 |
|
12,236 |
12,092 |
$572K |
| 84165 |
|
20,475 |
19,685 |
$570K |
| 87517 |
|
16,535 |
16,014 |
$522K |
| 86003 |
|
19,494 |
19,369 |
$511K |
| 87536 |
|
10,213 |
10,040 |
$496K |
| 87340 |
|
112,368 |
111,217 |
$420K |
| 82570 |
|
85,625 |
78,821 |
$401K |
| 36415 |
Collection of venous blood by venipuncture |
143,195 |
140,742 |
$312K |
| 83516 |
|
35,241 |
35,093 |
$296K |
| 88142 |
|
76,681 |
76,474 |
$276K |
| 88312 |
|
4,175 |
4,058 |
$245K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,352 |
2,333 |
$236K |
| 88344 |
|
1,305 |
1,284 |
$225K |
| 86706 |
|
49,078 |
48,770 |
$224K |
| 86140 |
|
89,862 |
86,273 |
$212K |
| 86704 |
|
31,752 |
31,474 |
$199K |
| 82784 |
|
17,025 |
16,146 |
$165K |
| 88313 |
|
2,108 |
2,048 |
$162K |
| 88184 |
|
1,840 |
1,752 |
$156K |
| 88360 |
|
624 |
605 |
$152K |
| 83020 |
|
12,964 |
12,875 |
$143K |
| 86225 |
|
19,095 |
18,728 |
$137K |
| 88112 |
|
4,144 |
4,049 |
$135K |
| 87209 |
|
18,526 |
18,297 |
$132K |
| 84156 |
|
58,747 |
53,945 |
$130K |
| 87070 |
|
29,036 |
27,571 |
$121K |
| 87631 |
|
11,314 |
11,180 |
$119K |
| 86334 |
|
2,381 |
2,339 |
$118K |
| 88189 |
|
1,338 |
1,289 |
$117K |
| 87529 |
|
9,899 |
9,740 |
$114K |
| 86038 |
|
17,644 |
17,522 |
$106K |
| 86762 |
|
30,203 |
30,057 |
$102K |
| 86160 |
|
12,369 |
9,808 |
$100K |
| 87329 |
|
18,030 |
17,813 |
$92K |
| 87522 |
Neg quan hep c or qual rna |
3,772 |
3,681 |
$91K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,046 |
3,997 |
$73K |
| 88173 |
|
1,003 |
983 |
$69K |
| 84134 |
|
5,083 |
4,736 |
$67K |
| 86665 |
|
8,697 |
8,639 |
$67K |
| 86200 |
|
11,413 |
11,361 |
$66K |
| 87102 |
|
24,953 |
24,281 |
$63K |
| 88307 |
|
748 |
747 |
$62K |
| 86708 |
|
10,779 |
10,739 |
$55K |
| 86255 |
|
3,207 |
3,160 |
$55K |
| 83498 |
|
7,001 |
6,975 |
$52K |
| 87521 |
Neg quan hep c or qual rna |
1,815 |
1,785 |
$48K |
| 88365 |
|
226 |
225 |
$47K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,976 |
6,905 |
$47K |
| 86480 |
|
971 |
969 |
$46K |
| 88304 |
|
4,483 |
4,449 |
$42K |
| 86431 |
|
15,579 |
15,501 |
$42K |
| 84466 |
|
5,667 |
5,599 |
$42K |
| 86787 |
|
13,854 |
13,780 |
$38K |
| 87081 |
|
26,345 |
26,119 |
$37K |
| 87040 |
|
6,410 |
5,213 |
$35K |
| 86664 |
|
8,691 |
8,631 |
$30K |
| 87116 |
|
3,254 |
2,097 |
$30K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
3,060 |
2,546 |
$26K |
| 83010 |
|
2,528 |
2,256 |
$26K |
| 82390 |
|
4,919 |
4,890 |
$25K |
| 82103 |
|
3,556 |
3,541 |
$24K |
| 86765 |
|
10,641 |
10,569 |
$24K |
| 86709 |
|
4,365 |
4,343 |
$23K |
| 86735 |
|
9,925 |
9,868 |
$23K |
| 86696 |
|
3,704 |
3,688 |
$22K |
| 87538 |
|
1,316 |
1,294 |
$19K |
| 82384 |
|
864 |
858 |
$19K |
| 86593 |
|
10,017 |
9,729 |
$19K |
| 87535 |
|
1,250 |
1,228 |
$19K |
| 82164 |
|
1,988 |
1,972 |
$16K |
| 87075 |
|
1,496 |
1,457 |
$15K |
| 86769 |
|
1,881 |
1,876 |
$14K |
| 86695 |
|
3,239 |
3,221 |
$14K |
| 87206 |
|
3,218 |
2,070 |
$13K |
| 83835 |
|
1,032 |
1,024 |
$13K |
| 85097 |
|
165 |
163 |
$13K |
| 88364 |
|
62 |
62 |
$13K |
| 82239 |
|
2,439 |
2,160 |
$13K |
| 83695 |
|
2,605 |
2,597 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,322 |
1,299 |
$8K |
| 86008 |
|
399 |
329 |
$6K |
| 86335 |
|
44 |
44 |
$5K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
569 |
561 |
$5K |
| 82955 |
|
1,017 |
1,014 |
$5K |
| 82530 |
|
344 |
339 |
$5K |
| 84166 |
|
56 |
56 |
$4K |
| 88104 |
|
37 |
37 |
$4K |
| 87328 |
|
598 |
588 |
$3K |
| 83883 |
|
92 |
57 |
$3K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
116 |
110 |
$3K |
| 86060 |
|
1,080 |
1,068 |
$3K |
| 82340 |
|
191 |
189 |
$2K |
| 86162 |
|
121 |
120 |
$1K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
67 |
62 |
$1K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
20 |
20 |
$756.31 |
| 86677 |
|
2,270 |
2,263 |
$611.10 |
| 88108 |
|
26 |
25 |
$352.62 |
| 86618 |
|
577 |
572 |
$306.98 |
| 87045 |
|
81 |
80 |
$304.88 |
| 86705 |
|
19 |
19 |
$280.00 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
841 |
776 |
$265.20 |
| 87177 |
|
31 |
28 |
$217.95 |
| 87327 |
|
13 |
13 |
$200.00 |
| 87172 |
|
54 |
52 |
$154.18 |
| 87350 |
|
422 |
411 |
$145.56 |
| 82310 |
|
13 |
13 |
$95.06 |
| 86707 |
|
263 |
255 |
$44.36 |
| 87799 |
|
223 |
206 |
$39.11 |
| 86320 |
|
272 |
263 |
$23.93 |
| 88141 |
|
47 |
47 |
$10.53 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
598 |
595 |
$0.00 |
| 87902 |
|
43 |
43 |
$0.00 |
| G0143 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision |
480 |
478 |
$0.00 |
| 3078F |
|
61 |
51 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12 |
12 |
$0.00 |
| 90658 |
|
63 |
63 |
$0.00 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
1,483 |
1,470 |
$0.00 |
| 90674 |
|
20 |
20 |
$0.00 |
| 86580 |
|
16 |
15 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12 |
12 |
$0.00 |
| 90656 |
|
12 |
12 |
$0.00 |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
26 |
25 |
$0.00 |
| 3074F |
|
63 |
53 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
147 |
142 |
$0.00 |
| 90686 |
|
64 |
63 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
20 |
20 |
$0.00 |